2025 Silent Capital Report now available. Where family offices and LPs are actually deploying. [Download for free →]
About usSign in
Status
ACTIVE
Global HQ
San Francisco, United States
Countries of investment
  • United States
Investment stages
  • Seed
  • Series A
  • Series B
Industries
  • Biotechnology
  • Life Sciences
  • Precision Medicine
  • Diagnostics
  • Digital Health
  • Health Tech
  • Biologics
  • AI
  • Pharma
About
Yosemite is a San Francisco-based, cancer-focused venture firm founded by Reed Jobs, spun out of Laurene Powell Jobs's Emerson Collective in 2023 and managing more than $1B including holdings carried over from Emerson. Its first fund closed at $263M in 2024 after a $200M first close in 2023. In November 2026 it held the final close of its oversubscribed second fund at $350M, up from a $200M first close in January 2026, with limited partners including Amgen, AbbVie, MIT, Memorial Sloan Kettering and John Doerr. Fund II plans to back about 25 companies, with several incubations underway including in radiopharmaceuticals, alongside philanthropic grants to academic researchers that have exceeded $18M since 2023, partly through a partnership with the American Cancer Society. Portfolio companies include Chai Discovery, Tune Therapeutics, Azalea Therapeutics and Teal Health.
Min check size
$5M
Max check size
$15M
Fund size
NPS

Investment Thesis

Yosemite invests exclusively in oncology, backing early-stage therapeutics, diagnostics, tools and digital health companies with the stated goal of making cancer non-lethal within our lifetime. It focuses mainly on pre-IND and early clinical companies, often first-in-class, and helps create about a third of its venture companies itself, many of them emerging from academic labs it has funded. Its edge is a hybrid model that pairs the venture fund with a donor-advised philanthropic vehicle giving no-strings research grants to academic scientists, which gives it early access to investable science.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

Reed Jobs joined Emerson Collective at 24 in 2015 to lead its oncology-focused health strategy and became its Managing Director of Health, supporting hundreds of researchers and investing in dozens of therapeutic, diagnostic and digital health companies before spinning the team out as Yosemite in 2023. Daniel McHugh, head of the investment team, came from the same Emerson health team and served as interim CEO of portfolio company Tune Therapeutics in 2024. Matt Bettonville leads digital health and care delivery investments after working on Emerson's Count Me In partnership with the Broad Institute and as a software engineer at Apple.

Yosemite Contacts Information

Primary contact

Secondary contact

Team

Reed Jobs - Founder and Managing Partner

Daniel McHugh - Head of Investment Team

Matt Bettonville - Investor

Beverly Lu - Investor

Portfolio

Chai Discovery

Tune Therapeutics

Azalea Therapeutics

Teal Health

Quarry Therapeutics

HistoSonics

Sage Care

Turquoise Health

Atropos Health

1063 Therapeutics

Fund number
Year Founded
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp